Medical agencies against abortion want federal officials to tighten the restrictions on MIFEPRISTONE abortion.
On July 8, six medical groups-including the American Association of Obstetricians and Gynecologists and Gynecologists and the Alliance for Hippocrates Medicine-are named by the Minister of Health and Human Services Robert F. Kennedy Jr. and Marty Makary Food and Drug Administration Commissioner to require patients to take ultrasound and receive Mifepristone in-Person from an approved provider. MIFEPristone, one of the two drugs commonly used in drug abortion, is used in over half of all abortions in the US
The letterwhich were First reported by Fox NewsHe also asked the organizations to reduce the approved deadline for when the drug can be used to terminate pregnancy from ten weeks to seven weeks pregnancy and extend the drug -related side effects report.
The letter stated extremely critical survey indicating a much higher percentage of serious health consequences associated with MIFEPristone by most of Current scientific evidence indicates.
Mimeteristonewhich prevents the basic pregnancy hormone, has been approved by the FDA for more than two decades. It works in conjunction with Misoprostol, which causes the uterine to leave to effectively terminate pregnancies. (Mifepristone is also used in another usual gynecological care, including procedures that allow surgeons to examine the interior of the uterus and the introduction of intrauterine devices.)
Although it is possible to have an abortion of drugs without MIFEPristone, studies indicate the use of increases efficiency of a drug abortion from a about 80 % success rate in 90 %.
The request of the groups against abortion comes in the midst of a unprecedented shake in the National Health Policy under Kennedy, who has adopted a long time Anti-vaccination opinions and referring Poor quality research or seconded science To explain attitudes. In May 2025, Kennedy told legislators that he believed that the Mifepristone label would have to change “at least” and direct Makary to revise the safety of the drug.
HHS did not immediately respond to a request for comments about calling groups against abortion to redefine the stricter restrictions on the drug amid FDA security review, which many doctors and supporters It is already believed to be unnecessary, they are complete. If these organizations will act on their request, access to the drug could be seriously obstructed, experts said Rewire News Group.
“We expect that continuous efforts such as this will intervene and prevent access to Mifepristone, but science is clear that Mifepristone is safe, effective, and that cases of serious complication are extremely rare,” said Molly Meegan, a leading legal officer and a general adviser to the US College. Corner. “The FDA must be based on the decades of scientific evidence and data that proves the safety and efficacy of Mifepristone when making decisions about access to this basic medicine.”
Between 2011 and 2016The FDA has set restrictions almost identical to those required by the letter. The restrictions were subsequently raised gradually over the years. Sub Current FDA InstructionsMifepristone can be prescribed by an approved provider to terminate pregnancies for up to 10 weeks of pregnancy without a personal visit. Patients can take the drug from pharmacies Certified to distribute it, except for medical facilities.
Previous, more restrictive requirements did not rely on MIFEPRISTONE security data And he created “unnecessary obstacles that really harm patients’ care,” Dr. Corner.
Lincoln, who founded a website This trains people about how to access abortions, emergency contraception and post -mail birth control, he added that previous care requirements on the person had not been “proven benefit” and that the reduction of the pregnancy age from ten weeks to seven would be “disastrous”.
“Many people do not even realize that they are pregnant up to 4-6 weeks since their last [proposed] Arbitrary seven -week restriction, “he wrote.
“Approval and regulation of FDA drugs should be based on clinical trials evaluated by peer, risk-benefit analysis using established methodologies and post-purchase surveillance data,” Lincoln added. “The letter represents an attempt to bypass these established procedures with research driven by the agenda that does not meet scientific standards.”
Lincoln is worried that when it comes to Mifepristone, “politics will prevail events and science”.
“I have no current confidence that HHS and FDA will attract science and leave MIFEPRISTONE access as it is today-not because of the amazing people working there-but instead of these organizations have been hijacked by non-expert leaders who Lincoln.
This story develops and will be updated as new information is available.
